Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations

Yu,Yang; Wang,Xueer; Li,Qinglin; Zhang,Min; Xu,Pengcheng; Chen,Yinghua; Yan,Yuan; Zhang,Lin

doi:10.3892/ol.2017.7330

Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations

Authors:
- Yang Yu
- Xueer Wang
- Qinglin Li
- Min Zhang
- Pengcheng Xu
- Yinghua Chen
- Yuan Yan
- Lin Zhang
View Affiliations

Affiliations: Department of Histology and Embryology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: November 2, 2017 https://doi.org/10.3892/ol.2017.7330
Pages: 635-641

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melanoma is a highly malignant tumor of the skin melanocytes. Patients with this cancer have a high frequency (~50%) of oncogenic BRAF mutations, particularly BRAF V600E. Treatments for melanoma often target BRAF mutations or involve mitogen‑activated protein kinase kinase/extracellular signal‑regulated kinase inhibitors. A major challenge in melanoma treatment is resistance to BRAF inhibitor treatment, which may be enhanced by the BRAF mutation itself and/or epidermal growth factor receptor (EGFR) activation, leading to poor prognosis. However, no effective clinical treatment exists for patients with EGFR‑activating feedback. The aim of the present study was to analyze gene expression changes in tumors from patients with EGFR‑activating BRAF mutations during development of drug resistance. RNA‑seq data was downloaded from the Gene Expression Omnibus (GEO) database for pre‑ and post‑treatment tumor samples from three melanoma patients with EGFR‑activating BRAF V600E mutations, and from The Cancer Genome Atlas (TCGA) melanoma database for tumor and non‑tumor samples from patients with the BRAF V600E mutation and unknown EGFR activation status. Using functional enrichment and KEGG pathway analyses, the present study analyzed differentially expressed genes (DEGs) between pre‑ vs. post‑treatment data from the GEO database and tumor or non‑tumor sample data from the TCGA database. The results of the present study indicated that functional and structural changes to the plasma membrane may be associated with drug resistance. The present study identified 9 DEGs that were significantly different between tumor and non‑tumor samples and also between prior to and following treatment. Thus, it was confirmed that patients with EGFR‑activating BRAF V600E mutations undergo gene expression changes during disease development, and during therapy. These findings may provide potential directions for melanoma‑specific therapy.

View Figures

View References

1	Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
2	Clary BM, Brady MS, Lewis JJ and Coit DG: Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence. Ann Surg. 233:250–258. 2001. View Article : Google Scholar : PubMed/NCBI
3	Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
4	Flaherty KT, Hodi FS and Fisher DE: From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer. 12:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
5	Hartsough EJ, Basile KJ and Aplin AE: Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol Cancer Res. 12:795–802. 2014. View Article : Google Scholar : PubMed/NCBI
6	Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C and Marais R: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 140:209–221. 2010. View Article : Google Scholar : PubMed/NCBI
7	Vial E, Sahai E and Marshall CJ: ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell. 4:67–79. 2003. View Article : Google Scholar : PubMed/NCBI
8	Gautschi O, Pauli C, Strobel K, Hirschmann A, Printzen G, Aebi S and Diebold J: A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol. 7:e23–e24. 2012. View Article : Google Scholar : PubMed/NCBI
9	Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M and Stuart DD: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 494:251–255. 2013. View Article : Google Scholar : PubMed/NCBI
10	Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
11	McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, et al: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 16:483–489. 2010. View Article : Google Scholar : PubMed/NCBI
12	Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, et al: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One. 7:e353092012. View Article : Google Scholar : PubMed/NCBI
13	Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA and Riely GJ: Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design. Clin Cancer Res. 17:6298–6303. 2011. View Article : Google Scholar : PubMed/NCBI
14	Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Pelle P Della, Dias-Santagata D, Hung KE, et al: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2:227–235. 2012. View Article : Google Scholar : PubMed/NCBI
15	Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A and Bernards R: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 483:100–103. 2012. View Article : Google Scholar : PubMed/NCBI
16	Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, et al: Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 508:118–122. 2014. View Article : Google Scholar : PubMed/NCBI
17	Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 7:562–578. 2012. View Article : Google Scholar : PubMed/NCBI
18	Robinson MD, McCarthy DJ and Smyth GK: edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 26:139–140. 2010. View Article : Google Scholar : PubMed/NCBI
19	Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S and Becchetti A: Targeting ion channels in cancer: A novel frontier in antineoplastic therapy. Curr Med Chem. 16:66–93. 2009. View Article : Google Scholar : PubMed/NCBI
20	Cheli VT, González DA Santiago, Spreuer V and Paez PM: Voltage-gated Ca2+ entry promotes oligodendrocyte progenitor cell maturation and myelination in vitro. Exp Neurol. 265:69–83. 2015. View Article : Google Scholar : PubMed/NCBI
21	Tsavaler L, Shapero MH, Morkowski S and Laus R: Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 61:3760–3769. 2001.PubMed/NCBI
22	Imming P, Sinning C and Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 5:821–834. 2006. View Article : Google Scholar : PubMed/NCBI
23	Kunzelmann K: Ion channels and cancer. J Membr Biol. 205:159–173. 2005. View Article : Google Scholar : PubMed/NCBI
24	Chen X, Ji ZL and Chen YZ: TTD: Therapeutic target database. Nucleic Acids Res. 30:412–415. 2002. View Article : Google Scholar : PubMed/NCBI
25	Gurnett CA, Veile R, Zempel J, Blackburn L, Lovett M and Bowcock A: Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation. Arch Neurol. 65:550–553. 2008. View Article : Google Scholar : PubMed/NCBI
26	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
27	Neri D and Supuran CT: Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 10:767–777. 2011. View Article : Google Scholar : PubMed/NCBI
28	Ong GL, Goldenberg DM, Hansen HJ and Mattes MJ: Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology. 98:296–302. 1999. View Article : Google Scholar : PubMed/NCBI
29	Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA and Goldenberg DM: Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 163:478–486. 2013. View Article : Google Scholar : PubMed/NCBI
30	Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR and Ostrand-Rosenberg S: The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunol Immunother. 57:389–398. 2008. View Article : Google Scholar : PubMed/NCBI
31	Ruggero D and Pandolfi PP: Does the ribosome translate cancer? Nat Rev Cancer. 3:179–192. 2003. View Article : Google Scholar : PubMed/NCBI
32	Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, et al: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 65:521–530. 2004. View Article : Google Scholar : PubMed/NCBI